Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Intangibles (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Intangibles for 7 consecutive years, with $30.9 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 17.13% to $30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.9 million through Dec 2025, down 17.13% year-over-year, with the annual reading at $30.9 million for FY2025, 17.13% down from the prior year.
  • Intangibles hit $30.9 million in Q4 2025 for Eton Pharmaceuticals, down from $31.9 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $37.3 million in Q4 2024 to a low of $463000.0 in Q3 2021.
  • Historically, Intangibles has averaged $11.3 million across 5 years, with a median of $4.7 million in 2022.
  • Biggest five-year swings in Intangibles: decreased 24.35% in 2021 and later soared 974.08% in 2022.
  • Year by year, Intangibles stood at $3.6 million in 2021, then surged by 31.29% to $4.8 million in 2022, then decreased by 0.32% to $4.7 million in 2023, then skyrocketed by 686.28% to $37.3 million in 2024, then fell by 17.13% to $30.9 million in 2025.
  • Business Quant data shows Intangibles for ETON at $30.9 million in Q4 2025, $31.9 million in Q3 2025, and $32.9 million in Q2 2025.